Therefore, in addition to the effects on clonal expansion of tumor antigen–specific T cells, our data indicate that combination therapy with CTX and GITR engagement promotes highly cytolytic, terminally differentiated CD8+ T cells. This evidence concerns the gene TNFRSF18 and neoplasm.